DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Jefferies Financial Group increased their FY2018 EPS estimates for shares of DexCom in a research report issued to clients and investors on Tuesday, November 6th. Jefferies Financial Group analyst R. Denhoy now anticipates that the medical device company will post earnings per share of ($0.09) for the year, up from their previous estimate of ($0.25). Jefferies Financial Group currently has a “Buy” rating and a $148.00 price target on the stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2018 earnings at $0.17 EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.19 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.30 EPS.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.29. The firm had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. DexCom had a negative return on equity of 3.08% and a net margin of 4.72%. The business’s revenue for the quarter was up 44.5% on a year-over-year basis.
Several other brokerages have also commented on DXCM. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Saturday. Northland Securities upgraded DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Stephens lifted their target price on DexCom from $170.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Jaffray Companies lifted their target price on DexCom to $157.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Canaccord Genuity lifted their target price on DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $132.50.
Shares of DXCM opened at $149.46 on Friday. The company has a market capitalization of $11.74 billion, a PE ratio of -257.69 and a beta of 0.60. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69. DexCom has a 52 week low of $49.80 and a 52 week high of $152.14.
Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. Morgan Stanley lifted its holdings in shares of DexCom by 16.3% in the 2nd quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after purchasing an additional 705,072 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of DexCom by 67,520.1% in the 2nd quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock worth $46,948,000 after purchasing an additional 493,572 shares during the last quarter. Waddell & Reed Financial Inc. lifted its holdings in shares of DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after purchasing an additional 354,331 shares during the last quarter. Columbus Circle Investors lifted its holdings in shares of DexCom by 192.3% in the 2nd quarter. Columbus Circle Investors now owns 532,489 shares of the medical device company’s stock worth $50,576,000 after purchasing an additional 350,339 shares during the last quarter. Finally, Ardevora Asset Management LLP bought a new stake in shares of DexCom in the 3rd quarter worth approximately $36,654,000.
In related news, EVP Andrew K. Balo sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $124.25, for a total value of $621,250.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Donald Abbey sold 2,303 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $143.76, for a total value of $331,079.28. The disclosure for this sale can be found here. In the last three months, insiders sold 157,892 shares of company stock worth $21,864,030. Company insiders own 1.80% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.